• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

    4/2/25 8:02:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email

    NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD).

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The research collaboration is led by Dr. Carla M. Yuede, Professor in the Departments of Psychiatry, Neurology, and Neuroscience, and Director of the Animal Behavior Core at Washington University. The proposal, titled "Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement," aims to understand the precise neurological mechanisms and cellular targets responsible for the beneficial cognitive effects observed with HT-ALZ.

    In preclinical studies conducted at Washington University, chronic oral administration of HT-ALZ significantly improved cognitive functions, reduced anxiety-like behaviors, and decreased astrocyte-driven neuroinflammation in the APP/PS1 mouse model of Alzheimer's. Acute treatment also reduced brain interstitial fluid Aβ40 levels by approximately 15% within 20 hours.

    Robb Knie, Chief Executive Officer of Hoth Therapeutics, commented, "We are proud to support Dr. Yuede and her team at Washington University. This grant application represents a significant milestone in our commitment to understanding NK-1 receptor biology and its role in neurological diseases, specifically Alzheimer's. We believe that HT-ALZ, with its established safety profile, holds tremendous promise as a therapeutic intervention."

    The company has supplied GMP-quality HT-ALZ to Washington University to support these studies, ensuring adherence to the highest standards of preclinical research. If funded, the grant will further elucidate the cellular specificity of NK-1 receptor antagonism and its broader implications for treating neuroinflammatory conditions.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC 

    Email: [email protected]

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-collaborates-with-washington-university-on-nih-grant-application-advancing-alzheimers-program-using-nk-1-receptor-antagonist-ht-alz-302417942.html

    SOURCE Hoth Therapeutics, Inc.

    Get the next $HOTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    SEC Filings

    See more
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      5/2/25 8:20:24 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      4/15/25 8:25:26 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Hoth Therapeutics Inc.

      10-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      3/28/25 4:15:47 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO and President Knie Robb

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:55 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Springer Graig

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:06 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sarnoff David

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/21/24 4:15:05 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

      Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics. The newly issued patent secures broad claims covering antisense oligome

      4/17/25 8:01:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

      Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 inOpen-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Interim Results (Day 1–21): Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21.Rapid symptom relief was observed, with mean scores improving to 1.0 by Day 7.Some patients achieved complete resolution of pruritus within the 21-day period.HT-001 was well tolerated, with no treatment-related serious adverse events reported.NEW YORK, April 15, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a biopharmaceutical company focuse

      4/15/25 8:19:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

      NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD). The research collaboration is le

      4/2/25 8:02:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

      NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

      1/31/22 8:17:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/19/24 8:00:03 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/24 2:47:32 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Hoth Therapeutics Inc.

      SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/23 12:55:35 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/8/23 6:07:04 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care